Volume 3, Issue 12
An increase in GABA content in Hippocampus of Albino rats exposed to chronic restraint model and treated by Quetiapine for 3 weeks
Author: Sahar Mohamed Kamal Shams El Dine
Abstract: Quetiapine is a novel antipsychotic drug. However, there is limited clinical evidence regarding prescribing patterns for quetiapine when used as maintenance treatment for bipolar disorder. Thirty-six albino rats were divided into 3 equal groups: control normal group without exposure to chronic restraint for 6 hours daily/21 days, group received DMSO 5% (v:v), as a solvent of quetiapine, with exposure to chronic restraint for 6 hours daily/21 days and group received quetiapine 10 mg/kg/day ip for 3 weeks during exposure to chronic restraint for 6 hours daily/21 days. Intraperitoneal (ip) administration of quetiapine at a dose of 10 mg/kg/day for 3 weeks significantly (p<0.05) reduces the duration of immobility recorded by the forced swimming test (FST) and significantly (p<0.05) increases the contents of GABA neurotransmitter in hippocampus homogenates. The present study adds a positive implication of quetiapine, as an antipsychotic drug, on both the immobility and the reduction of GABA content in hippocampus of albino rats exposed restraint model for 21 days.
Download Full Article: Click Here
Support Us
If you are interested in supporting our work and would like to contribute, you are welcome to mail me at jpbr.anil@gmail.com or at info@thepharmajournal.com it will be a great help and will surely be appreciated.
